Related Experiment Video
Updated: Jul 11, 2026
Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
Published on: August 14, 2018
Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular
Matheus M de Gunst1, Marielle I Gallegos-Ruiz, Giuseppe Giaccone
1Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands. tdegunst@gmail.com
Background:
The presence of EGFR kinase domain mutations in a subset of NSCLC patients correlates with the response to treatment with the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Although most EGFR mutations detected are short deletions in exon 19 or the L858R point mutation in exon 21, more than 75 different EGFR kinase domain residues have been reported to be altered in NSCLC patients. The phenotypical consequences of different EGFR mutations may vary dramatically, but the majority of uncommon EGFR mutations have never been functionally evaluated.
Results:
We demonstrate that the relative kinase activity and erlotinib sensitivity of different EGFR mutants can be readily evaluated using transfection of an YFP-tagged fragment of the EGFR intracellular domain (YFP-EGFR-ICD), followed by immunofluorescence microscopy analysis. Using this assay, we show that the exon 20 insertions Ins770SVD and Ins774HV confer increased kinase activity, but no erlotinib sensitivity. We also show that, in contrast to the common L858R mutation, the uncommon exon 21 point mutations P848L and A859T appear to behave like functionally silent polymorphisms.
Conclusion:
The ability to rapidly obtain functional information on EGFR variants of unknown relevance using the YFP-EGFR-ICD assay might prove important in the future for the management of NSCLC patients bearing uncommon EGFR mutations. In addition, our assay may be used to determine the response of resistant EGFR mutants to novel second-generation TKIs.
Insights
A new assay evaluating the Epidermal Growth Factor Receptor (EGFR) intracellular domain (ICD) can assess kinase activity and drug sensitivity for non-small cell lung cancer (NSCLC) mutations. This method helps understand uncommon EGFR mutations and guide treatment decisions.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epidermal Growth Factor Receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) influence treatment response to tyrosine kinase inhibitors (TKIs).
- While common EGFR mutations are known, over 75 residues can be altered, with many uncommon mutations lacking functional evaluation.
- Understanding the functional impact of diverse EGFR mutations is crucial for personalized NSCLC therapy.
Purpose of the Study:
- To develop and validate a method for assessing the functional consequences of various EGFR kinase domain mutations.
- To evaluate the kinase activity and erlotinib sensitivity of specific uncommon EGFR mutations, including exon 20 insertions and exon 21 point mutations.
Main Methods:
- Utilized a Yellow Fluorescent Protein (YFP)-tagged EGFR intracellular domain (YFP-EGFR-ICD) construct for transfection.
- Employed immunofluorescence microscopy to analyze relative kinase activity and erlotinib sensitivity of EGFR mutants.
- Assessed specific mutations like exon 20 insertions (Ins770SVD, Ins774HV) and exon 21 variants (P848L, A859T).
Main Results:
- The YFP-EGFR-ICD assay effectively evaluated kinase activity and erlotinib sensitivity of different EGFR mutants.
- Exon 20 insertions Ins770SVD and Ins774HV demonstrated increased kinase activity but lacked erlotinib sensitivity.
- Uncommon exon 21 mutations P848L and A859T behaved as functionally silent polymorphisms, unlike the common L858R mutation.
Conclusions:
- The YFP-EGFR-ICD assay provides rapid functional insights into EGFR variants of unknown significance.
- This assay may aid in managing NSCLC patients with uncommon EGFR mutations.
- The methodology can potentially assess the response of resistant EGFR mutants to novel second-generation TKIs.
